Pharmacokinetics of arsenic species in Japanese patients with relapsed or refractory acute promyelocytic leukemia treated with arsenic trioxide

Cancer Chemotherapy and Pharmacology

Volumn 59, Issue 4, 2007, Pages 485-493

  Fujisawa, Shinya ^a   Ohno, Ryuzo ^b   Shigeno, Kazuyuki ^a   Sahara, Naohi ^a   Nakamura, Satoki ^a   Naito, Kensuke ^a   Kobayashi, Miki ^a   Shinjo, Kaori ^a   Takeshita, Akihiro ^a   Suzuki, Yoshinari ^c   Hashimoto, Hisakuni ^c   Kinoshita, Kenji ^d   Shimoya, Masahito ^d   Kaise, Toshikazu ^d   Ohnishi, Kazunori ^a  

^a HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b AICHI CANCER CENTER HOSPITAL   (Japan)

^c HAMAMATSU UNIVERSITY HOSPITAL   (Japan)

^d TOKYO UNIVERSITY OF PHARMACY AND LIFE SCIENCES   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ARSENIC; ARSENIC TRIOXIDE; CACODYLIC ACID; METHANEARSONIC ACID;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BLOOD ANALYSIS; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RELAPSE; CANCER RESISTANCE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG METABOLISM; DRUG URINE LEVEL; FEMALE; HUMAN; JAPAN; MALE; METHYLATION; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; REPEAT PROCEDURE; STEADY STATE; TREATMENT OUTCOME; URINALYSIS; URINARY EXCRETION;

ADULT; AGED; ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; ARSENIC; ARSENICALS; FEMALE; HUMANS; LEUKEMIA, PROMYELOCYTIC, ACUTE; MALE; MIDDLE AGED; OXIDES; PROSPECTIVE STUDIES;

EID: 33846266237     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-006-0288-4     Document Type: Article

References (25)

1. Sun HD, Ma L, Hu XC, Zhang TD (1992) Ai-Lin I treated 32 cases of acute promyelocytic leukemia. Chin J Integr Chin and West Med 12:170-171
2. Zhang P, Wang SY, Hu LH (1996) Arsenic trioxide treated 72 cases of acute promyelocytic leukemia. Chin J Hematol 17:58-62
3. 3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood 89:3354-3360
4. Soignet SL, Maslak P, Wang ZG, Jhanwar S, Calleja E, Dardashti LJ, Corso D, DeBlasio A, Gabrilove J, Scheinberg DA, Pandolfi PP, Warrell RP Jr (1998) Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N Engl J Med 339:1341-1348
5. Soignet SL, Frankel SR, Douer D, Tallman MS, Kantarjian H, Calleja E, Stone RM, Kalaycio M, Scheinberg DA, Steinherz P, Sievers EL, Coutre S, Dahlberg S, Ellison R, Warrell RP Jr (2001) United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. J Clin Oncol 19:3852-3860
6. Ohnishi K, Yoshida H, Shigeno K, Nakamura S, Fujisawa S, Naito K, Shinjo K, Fujita Y, Matsui H, Sahara N, Takeshita A, Satoh H, Terada H, Ohno R (2002) Arsenic trioxide therapy for relapsed or refractory Japanese patients with acute promyelocytic leukemia: need for careful electrocardiogram monitoring. Leukemia 16:617-622
7. Challenger F (1945) Biological methylation. Chem Rev 36:315-361
8. Cullen W. R, Reimer K. J (1989) Arsenic speciation in the environment. Chem Rev 89:713-764
9. Chen GQ, Zhou L, Styblo M, Walton F, Jing Y, Weinberg R, Chen Z, Waxman S (2003) Methylated metabolites of arsenic trioxide are more potent than arsenic trioxide as apoptotic but not differentiation inducers in leukemia and lymphoma cells. Cancer Res 63:1853-1859
10. Shen Y, Shen ZX, Yan H, Chen J, Zeng XY, Li JM, Li XS, Wu W, Xiong SM, Zhao WL, Tang W, Wu F, Liu YF, Niu C, Wang ZY, Chen SJ, Chen Z (2001) Studies on the clinical efficacy and pharmacokinetics of low-dose arsenic trioxide in the treatment of relapsed acute promyelocytic leukemia: a comparison with conventional dosage. Leukemia 15:735-741
11. Raffoux E, Rousselot P, Poupon J, Daniel MT, Cassinat B, Delarue R, Taksin AL, Rea D, Buzyn A, Tibi A, Lebbe G, Cimerman P, Chomienne C, Fermand JP, de The H, Degos L, Hermine O, Dombret H (2003) Combined treatment with arsenic trioxide and all-trans-retinoic acid in patients with relapsed acute promyelocytic leukemia. J Clin Oncol 21:2326-2334
12. Rousselot P, Larghero J, Arnulf B, Poupon J, Royer B, Tibi A, Madelaine-Chambrin I, Cimerman P, Chevret S, Hermine O, Dombret H, Claude Brouet J, Paul Fermand J (2004) A clinical and pharmacological study of arsenic trioxide in advanced multiple myeloma patients. Leukemia 18:1518-1521
13. Ishitsuka K, Shirahashi A, Iwao Y, Shishime M, Takamatsu Y, Takatsuka Y, Utsunomiya A, Suzumiya J, Hara S, Tamura K (2004) Bone marrow necrosis in a patient with acute promyelocytic leukemia during re-induction therapy with arsenic trioxide. Eur J Haematol 72:280-284
14. Westervelt P, Brown RA, Adkins DR, Khoury H, Curtin P, Hurd D, Luger SM, Ma MK, Ley TJ, DiPersio JF (2001) Sudden death among patients with acute promyelocytic leukemia treated with arsenic trioxide. Blood 98:266-271
15. Wang Z, Zhou J, Lu X, Gong Z, Le XC (2004) Arsenic speciation in urine from acute promyelocytic leukemia patients undergoing arsenic trioxide treatment. Chem Res Toxicol 17:95-103
16. Fukai Y, Hirata M, Ueno M, Ichikawa N, Kobayashi H, Saitoh H, Sakurai T, Kinoshita K, Kaise T, Ohta S (2006) Clinical pharmacokinetic study of arsenic trioxide in an acute promyelocytic leukemia (APL) patients: speciation of arsenic metabolites in serum and urine. Biol Pharm Bull 29:1022-1027
17. Kaise T, Watanabe S, Itoh K (1985) The acute toxicity of arsenobetaine. Chemosphere 14:1327-1332
18. Yamauchi H, Yamamura Y (1984) Metabolism and excretion of orally ingested trimethyl arsenic in man. Bull Environ Contam Toxicol 32:682-687
19. Benramdane L, Accominotti M, Fanton L, Malicier D, Vallon JJ (1999) Arsenic speciation in human organs following fatal arsenic trioxide poisoning - a case report. Clin Chem 45:301-306
20. Vasken Aposhian H, Zakharyan RA, Avram MD, Sampayo-Reyes A, Wollenberg ML (2004) A review of the enzymology of arsenic metabolism and a new potential role of hydrogen peroxide in the detoxication of the trivalent arsenic species. Toxicol Appl Pharmacol 198:327-335
21. Feldmann J, Lai VW, Cullen WR, Ma M, Lu X, Le XC (1999) Sample preparation and storage can change arsenic speciation in human urine. Clin Chem 45:1988-1997
22. Del Razo LM, Styblo M, Cullen WR, Thomas DJ (2001) Determination of trivalent methylated arsenicals in biological matrices. Toxicol Appl Pharmacol 174:282-293
23. Pomroy C, Charbonneau SM, McCullough RS, Tam GK (1980) Human retention studies with 74As. Toxicol Appl Pharmacol 53:550-556
24. Buchet.JP, Lauwerys R, Roels H (1981) Urinary excretion of inorganic arsenic and its metabolites after repeated ingestion of sodium meta-arsenite by volunteers. Int Arch Occup Environ Health 48:111-118
25. Mandal BK, Ogra Y, Anzai K, Suzuki KT (2004) Speciation of arsenic in biological samples. Toxicol Appl Pharmacol 198:307-318